

(For reference purpose only – Japanese version prevails in case of any discrepancy)

April 14, 2025

## **Notice Regarding Completion of Acquisition of Treasury Shares**

(Acquisition of treasury shares pursuant to the provisions of the Articles of Incorporation pursuant to Article 165-2 of the Companies Act of Japan)

Kaken Pharmaceutical Co., Ltd. (hereinafter referred to as the “Company”) hereby announces that the status of acquisition of treasury shares pursuant to the resolution to acquire treasury shares pursuant to Article 156 of the Companies Act of Japan as applied pursuant to Article 165-3 of the Companies Act of Japan.

The Company also announces that the current purchases conclude the share buyback based on a Board of Directors resolution on February 26, 2025.

(1) Class of shares acquired:	Common shares of the Company
(2) Acquisition period:	From April 1, 2025 to April 11, 2025
(3) Total number of shares acquired:	538,800 shares
(4) Total amount of acquisition cost:	2,340,602,600 yen
(5) Acquisition method:	Market purchase

### (Reference)

#### I. Details of acquisition of treasury shares

(1) Class of shares to be acquired:	Common shares of the Company
(2) Total number of shares to be acquired:	Up to a maximum of 1.8 million shares (4.52% of the total number of shares issued (excluding treasury shares))
(3) Total amount of acquisition cost:	Up to a maximum of 9,000 million yen
(4) Acquisition period:	From February 27, 2025 to September 30, 2025

#### II. Cumulative total of treasury shares acquired (as of April 11, 2025)

(1) Total number of shares acquired:	1,800,000 shares
(2) Total amount of acquisition cost:	8,273,755,600 yen